Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of EBIT Margin data on file, last reported at 124.26% in Q1 2026.

• EBIT Margin for Q1 2026 came in at 124.26%, down 2139.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 83.78% (up 326.0% YoY), and the FY2025 annual result was 79.49%, up 1622.0% from the prior year.
• EBIT Margin declined to 124.26% in Q1 2026 per RARE's latest filing, from 54.65% in the prior quarter.
• Over five years, EBIT Margin peaked at 54.65% in Q4 2025 and troughed at 248.14% in Q3 2022.
• A 5-year average of 123.86% and a median of 124.26% in 2026 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin plunged 13812 bps in 2022, then jumped 10016 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 140.91% in 2022, then soared by 32 bps to 95.83% in 2023, then increased by 22 bps to 74.28% in 2024, then gained by 26 bps to 54.65% in 2025, then slumped by 127 bps to 124.26% in 2026.
• Business Quant data shows RARE's EBIT Margin at 124.26% in Q1 2026, 54.65% in Q4 2025, and 106.85% in Q3 2025.